11.30 Greg Craven: Quantitative irreversible tethering for covalent drug discovery
11.45 Tom Lanyon-Hogg: Chemical probes for hedgehog acyltransferase, a therapeutic arget in cancer
12.00 Main visiting speaker – Dr Lyn Jones: Advancing drug discovery using reactive chemical probes and chemogenomic profiling
Abstract
Chemical biology continues to significantly impact drug discovery research. This talk will describe the development of sulfonyl fluoride chemical probes to assess drug-target engagement and selectivity in live cells and to map new small molecule binding sites in proteins. Through these efforts probes were created that selectively engaged noncatalytic tyrosine, serine and threonine residues for the first time. Chemogenomic profiling will also be presented to identify new therapeutic targets from phenotypic screens.
Biography
Lyn Jones worked at Pfizer for 16 years, most recently as Head of Rare Disease Chemistry and leader of the Chemical Biology Group. In 2017 he decided to leave Pfizer to help create Jnana Therapeutics (Boston, USA) where he is currently Vice President of Chemical Biology.
His PhD studies were in total synthesis at Nottingham University, and he completed postdoctoral research in chemical biology at The Scripps Research Institute (La Jolla, USA). His research interests include the development of novel chemical methods to understand biology and disease. He has published over 100 papers in the areas of chemical biology and medicinal chemistry.